Search
Close this search box.

Cystic Fibrosis

VX19-445-115

STUDY OUTLINE

This clinical trial is a Phase 3b Open-label Study Evaluating the Safety of Elexacaftor/Tezacaftor/Ivacaftor Combination Therapy in Cystic Fibrosis Subjects.

The study aims to evaluate the safety and tolerability of VX-445 (elexacaftor)/tezacaftor/ivacaftor in Cystic Fibrosis patients homozygous for F508del (F/F).

To find out if this trial is suitable for you please register below or contact our Clinical Trials Team at admin@resphealth.uwa.edu.au or phone 6151 0888.

ELIGIBILITY & REQUIREMENTS

  • Aged 18 or over with a diagnosis of Cystic Fibrosis and an F/F genotype.
  • Completed the parent study VX18-445-109.
  • Not pregnant or breastfeeding.

WHAT'S INVOLVED

  • The total study duration is approximately 52 weeks (from the first dose of study drug), including a Treatment Period of 48 weeks and a 4-week Safety Follow-up Visit.
  • It involves up to 8 visits to the Institute for Respiratory Health at the QEII Medical Centre in Nedlands and up to 7 phone calls.

THIS CLINICAL TRIAL IS CURRENTLY CLOSED

Please register your interest for future clinical trials and we will contact you when a suitable trial becomes available.

Scroll to Top